このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Synairgen 将来の成長

Future 基準チェック /06

Synairgen は収益が増加すると予測されています。EPS は、年間増加すると予測されています40.6%。

主要情報

40.6%

収益成長率

40.6%

EPS成長率

Biotechs 収益成長	26.8%
収益成長率	n/a
将来の株主資本利益率	-67.5%
アナリストカバレッジ	Low
最終更新日	06 May 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Dec 09

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Feb 06

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Oct 21

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Mar 29

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

Dec 14

業績と収益の成長予測

AIM:SNG - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2023	N/A	-10	-4	-4	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-18	-14	-14	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-28	-28	-28	N/A
3/31/2022	N/A	-38	-35	-35	N/A
12/31/2021	N/A	-49	-41	-41	N/A
9/30/2021	N/A	-46	-44	-44	N/A
6/30/2021	N/A	-43	-48	-48	N/A
3/31/2021	N/A	-28	-36	-36	N/A
12/31/2020	N/A	-14	-24	-24	N/A
9/30/2020	N/A	-10	-15	-15	N/A
6/30/2020	N/A	-6	-6	-6	N/A
3/31/2020	N/A	-5	-4	-4	N/A
12/31/2019	N/A	-4	-3	-3	N/A
9/30/2019	0	-4	-4	-4	N/A
6/30/2019	0	-4	-4	-4	N/A
3/31/2019	0	-3	-4	-4	N/A
12/31/2018	0	-3	-4	-4	N/A
9/30/2018	3	-1	-1	-1	N/A
6/30/2018	5	2	2	2	N/A
3/31/2018	5	2	2	2	N/A
12/31/2017	5	2	2	2	N/A
9/30/2017	3	0	-1	-1	N/A
6/30/2017	0	-3	-3	-3	N/A
3/31/2017	0	-3	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A
9/30/2016	N/A	-3	N/A	-3	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-2	N/A
9/30/2015	0	-2	N/A	-2	N/A
6/30/2015	0	-2	N/A	-2	N/A
3/31/2015	2	0	N/A	0	N/A
12/31/2014	4	1	N/A	2	N/A
9/30/2014	4	1	N/A	2	N/A
6/30/2014	4	1	N/A	3	N/A
3/31/2014	2	-1	N/A	0	N/A
12/31/2013	N/A	-2	N/A	-2	N/A
9/30/2013	N/A	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SNG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SNG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SNG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SNGの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: SNGの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SNG 3 年以内に赤字になると予測されています。

Synairgen 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to UK£2.20

Price target decreased to UK£2.20

Recent updates

New major risk - Share price stability

New minor risk - Financial data availability

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

New major risk - Share price stability

Synairgen plc Announces Executive Changes

Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer

Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Synairgen plc, Annual General Meeting, Jun 29, 2023

Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research

Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee

Price target decreased to UK£2.20

No independent directors

Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health (Nih)/ Aids Clinical Trials Group (Actg)-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19

Synairgen plc Announces Changes to Its Board

Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients

Synairgen plc Announces Collaboration on Universal Trial

Synairgen plc, Annual General Meeting, Jun 30, 2022

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Less than half of directors are independent

Synairgen plc to Report Fiscal Year 2021 Results on May 25, 2022

Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants

Price target decreased to UK£2.20

Synairgen plc Announces Topline Results from Phase 3 SPRINTER trial of SNG001

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Synairgen plc Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Synairgen plc Announces Results of in Vitro Studies

Synairgen Announces Data from Home Cohort of SG016 Phase II Trial of Inhaled Interferon Beta in COVID-19 Patients and Encouraging Combined Data for Whole SG016 Trial

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Synairgen Announces Dosing Has Commenced with Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients

New 90-day high: UK£1.90

New 90-day high: UK£1.88

Synairgen Announces Inclusion of Its Inhaled Interferon Beta Treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc Announces Completion of Recruitment into Its Phase Ii Home-Based Covid-19 Study of Inhaled Interferon Beta

Synairgen Announces Commencement of Dosing in Its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients

Synairgen plc Provides COVID-19 Clinical Programme Update

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

New 90-day low: UK£0.77

Clinigen Group plc Signs Managed Access Program Agreement with Synairgen plc

New 90-day high - UK£2.32

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘